Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Methodist Hospital Research Institute |
| Country | United States |
| Start Date | Aug 01, 2023 |
| End Date | Jul 31, 2028 |
| Duration | 1,826 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10704861 |
PROJECT SUMMARY Blood CD8+ T cells can be subdivided into different subsets based on their cytokine section profiles and functions. We have shown that IL-9-secreting CD8+ Tc9 cells mediate a stronger antitumor effect in vivo compared to the classical IFN--secreting Tc1 or CTLs. However, the underlying mechanisms remain unclear.
Recently, we discovered that Tc9 cells could eradicate large-established tumors by inducing an enhanced tumor pyroptosis, a form of programmed cell death dependent on caspase-1 activation. Our preliminary studies showed that Tc9 cell-treated tumors had increased expressions of IL-1 and IL-18 and activated caspase-1,
and more tumor cell death compared to Tc1-treated tumors. Neutralizing IL-1 and IL-18 in vivo completely abrogated the therapeutic advantage of Tc9 cells over Tc1 cells in tumor controls. We further showed that tumor-specific Tc9 cells killed tumor cells by inducing both caspase-1-depedent pyroptosis and caspase-3-
dependent apoptosis while Tc1 cells mainly induced apoptosis in tumor cells. Similarly, human tumor-specific Tc9 cells also displayed stronger antitumor effects in vivo compared to Tc1 cells, which was IL-1- and IL-18- dependent. Interestingly, we observed that IL-1 plus IL-18 induced apoptosis in cultured Tc1 but not Tc9 cells,
Tc9 cell-derived IL-9 is critical for Tc9 cell activation of STAT3 and pro-growth and survival signaling and function, and IL-1 plus IL-18 can re-activate STAT3 and pro-growth and survival signaling in aged Tc9 cells with reduced IL-9 production. Thus, these findings reveal novel mechanisms underlying how Tc9 cells
overcome the suppressive tumor microenvironment after transfer, survive and persist longer, and exert a greater antitumor activity as compared to the traditional Tc1 cells. We hypothesize that tumor-specific Tc9 subset may be superb effector T cells for cancer immunotherapy due to their capacity to induce both
pyroptosis and apoptosis in tumor cells and utilize Tc9 cell-secreted IL-9 and tumor-produced IL-1 and IL-18 for their fitness, longevity, and function in vivo to effectively eradicate large established tumors. To test our hypothesis, Aim 1 will determine the importance and mechanisms of Tc9 cell-induced tumor cell pyroptosis in
tumor clearance via IL-9- and GrzB-induced NFB-NLRP3-caspase-1-gasdermin activation, and Aim 2 will determine the role and mechanisms underlying Tc9 cell persistence and function mediated by Tc9 cell- secreted IL-9 and tumor-produced IL-1 and IL-18. Completing this project will reveal the importance and
mechanism in induction of tumor pyroptosis by tumor-specific Tc9 cells and elucidate the mechanisms underlying the longevity and function of Tc9 cells in tumor microenvironment.
Methodist Hospital Research Institute
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant